Lille ; Cambridge ; Zurich ; September 26, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the.
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); September 26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients
Lille ; Cambridge ; Zurich ; August 10, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the. -Today at 04:11 pm- MarketScreener
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); August 10, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients
Pegozafermin was associated with improvements in fibrosis and could contribute to a resolution of NASH, according to the results of the phase 2b ENLIVEN trial.